C1B domain peptide of protein kinase Cγ significantly suppresses growth of human colon cancer cells in vitro and in an in vivo mouse xenograft model through induction of cell cycle arrest and apoptosis.
Two peptides derived from the C1B domain of protein kinase Cγ (PKCγ) were shown to associate with classical PKC isozymes and modulate their activities. These C1B peptides are designated C1B1 (amino acid residues 101-112) and C1B5 (residues 141-151). Since PKC enzyme activity is shown to be involved in colon cancer development, the effect of C1B peptides on the growth of various human colon cancer cell lines was examined in vitro and in vivo. Sub-micromolar to micromolar levels of both C1B peptides induced approximately 60-70% growth attenuation in multiple colon cancer cell lines in a soft agar tumor colony assay; however, C1B5 peptide was not cytotoxic to normal colon epithelial cells in two dimensional culture. The effect of C1B5 peptide on colony growth of COLO205 cells was reversed by treatment with the PKCα/β inhibitor, Ro-32-0432. C1B peptide treatment attenuated COLO205 cells via two mechanisms: 1) cell cycle arrest and 2) stimulation of apoptosis. This is evident in G 2 arrest and increases in levels of cleaved caspase 3 and p53 phosphorylated at serine 20. Intratumoral injection of C1B5 peptide (20 mg/kg/day, every three days) markedly attenuated the growth of subcutaneous xenografts of COLO205 cells in SCID mice by 76% compared with the control. Taken together, these results strongly suggest that C1B peptides have negligible effects on normal tissues but are potentially effective chemotherapeutic agents for colon cancer.
Department of Anatomy and Physiology, Kansas State University College of Veterinary Medicine, Manhattan, KS, USA.
Atsushi
A
Kawabata
Takaya
T
Matsuzuka
Chiyo
C
Doi
Garret
G
Seiler
Jennifer
J
Reischman
Lara
L
Pickel
Rie
R
Ayuzawa
Thu A
TA
Nguyen
Masaaki
M
Tamura
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D015552:Injections, Intralesional; D007527:Isoenzymes / Q000737:chemistry / Q000378:metabolism; D051379:Mice; D016513:Mice, SCID; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects; D054730:Protein Interaction Domains and Motifs; D011493:Protein Kinase C / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology; D012694:Serine / Q000378:metabolism; D047368:Tumor Burden / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D007211:Indoles; D007527:Isoenzymes; D010446:Peptide Fragments; D010455:Peptides; D011758:Pyrroles; D016159:Tumor Suppressor Protein p53; C085989:Ro 32-0432; D012694:Serine; C087857:protein kinase C gamma; D011493:Protein Kinase C; C576752:protein kinase C gamma (101-112); C576769:protein kinase C gamma (141-151)